Identification of positron emission tomography (PET) tracer candidates by prediction of the target-bound fraction in the brain

Psychonomic Bulletin and Review

Volumn 4, Issue 1, 1997, Pages

  Fridén, Markus ^a,b   Wennerberg, Marie ^a   Antonsson, Madeleine ^a   Sandberg Ställ, Maria ^c   Farde, Lars ^d   Schou, Magnus ^d  

^a ASTRAZENECA R AND D   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Imaging; Non specific binding; Positron emission tomography; Receptor occupancy

Indexed keywords

EID: 84930793546     PISSN: 10699384     EISSN: 15315320     Source Type: Journal    
DOI: 10.1186/s13550-014-0050-6     Document Type: Article

References (15)

1. Pike VW: PET radiotracers: crossing the blood–brain barrier and surviving metabolism.Trends Pharmacol Sci 2009, 30:431–440.
2. Halldin C, Gulyas B, Langer O, Farde L: Brain radioligands–state of the art and new trends.Q J Nucl Med 2001, 45:139–152.
3. Cunningham VJ, Parker CA, Rabiner EA, Gee AD, Gunn RN: PET studies in drug development: methodological considerations.Drug Discov Today 2005, 2:311–315.
4. Waterhouse RN: Determination of lipophilicity and its use as a predictor of blood–brain barrier penetration of molecular imaging agents.Mol Imaging Biol 2003, 5:376–389.
5. Patel S, Gibson R: In vivo site-directed radiotracers: a mini-review.Nucl Med Biol 2008, 35:805–815.
6. Rosso L, Gee AD, Gould IR: Ab initio computational study of positron emission tomography ligands interacting with lipid molecule for the prediction of nonspecific binding.J Comput Chem 2008, 29:2397–2405.
7. Jiang Z, Reilly J, Everatt B, Briard E: A rapid vesicle electrokinetic chromatography method for the in vitro prediction of non-specific binding for potential PET ligands.J Pharm Biomed Anal 2011, 54:722–729.
8. Guo Q, Brady M, Gunn RN: A biomathematical modeling approach to central nervous system radioligand discovery and development.J Nucl Med 2009, 50:1715–1723.
9. Guo Q, Owen DR, Rabiner EA, Turkheimer FE, Gunn RN: Identifying improved TSPO PET imaging probes through biomathematics: the impact of multiple TSPO binding sites in vivo.Neuroimage 2012, 60:902–910.
10. Zhang L, Villalobos A, Beck EM, Bocan T, Chappie TA, Chen L, Grimwood S, Heck SD, Helal CJ, Hou X, Humphrey JM, Lu J, Skaddan MB, McCarthy TJ, Verhoest PR, Wager TT, Zasadny K: Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand.J Med Chem 2013, 56:4568–4579.
11. Friden M, Ducrozet F, Antonsson M, Middleton B, Bredberg U, Hammarlund-Udenaes M: Development of a high-throughput brain slice method for studying drug distribution in the CNS.Drug Metab Dispos 2009, 37:1226.
12. Friden M, Bergstrom F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, Bredberg U: Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.Drug Metab Dispos 2011, 39:353–362.
13. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE: Consensus nomenclature for in vivo imaging of reversibly binding radioligands.J Cereb Blood Flow Metable 2007, 27:1533–1539.
14. Hammarlund-Udenaes M, Friden M, Syvanen S, Gupta A: On the rate and extent of drug delivery to the brain.Pharm Res 2008, 25:1737–1750.
15. Farde L, Eriksson L, Blomquist G, Halldin C: Kinetic analysis of central [llC]Raclopride binding to D2-dopamine receptors studied by PET-a comparison to the equilibrium analysis.J Cereb Blood Flow Metable 1989, 9:696–708.